Reason for request
Inclusion
Clinical Benefit
Substantial |
The actual benefit of BEXSERO is substantial in the active immunisation against invasive serogroup B meningococcal disease, but only in the populations recommended by the Haut Conseil de la Santé Publique in its opinion of 25 October 2013.
|
Clinical Added Value
important |
On the basis of the available data, the Committee considers that BEXSERO provides a substantial improvement in actual benefit (IAB II) in the prevention of invasive serogroup B meningococcal disease in the populations recommended by the Haut Conseil de la Santé Publique.
|
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
hmFTnGVhPCmrxsZg